<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the third most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in the US </plain></SENT>
<SENT sid="1" pm="."><plain>In recent decades, an improved understanding of the role of the <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> pathway in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> has led to advancements in treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, and at present is the only antiangiogenesis agent approved for the treatment of this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Aflibercept is a novel <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>-targeting agent, and has demonstrated efficacy in treating <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> in a recent randomized Phase III trial </plain></SENT>
<SENT sid="4" pm="."><plain>Here we review the role of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in the <z:mp ids='MP_0002006'>tumorigenesis</z:mp> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, strategies for targeting <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and the clinical development of aflibercept </plain></SENT>
</text></document>